Wockhardt Ltd management interview: 'We Need to Change the Ecosystem', Habil Khorakiwala on India's Pharma Future | Breaking
Moneycontrol, 2026-10-28. Video: https://www.youtube.com/watch?v=Fox-S33UvXM
- Antibiotic innovation: Wockhardt’s new-drug effort began about 25 years ago. Khorakiwala called Zaynich the first Indian new chemical entity to receive full FDA approval and a path-breaking antibiotic for multidrug-resistant gram-negative infections, which he said cause 1 million deaths annually in India and about 5 million globally; he expects half a dozen products over the next 10 years.
- Innovation ecosystem: Khorakiwala said India needs a regulatory system designed for innovative drugs, science-based and professional administration of clinical trials, and stronger confidence on intellectual property. He cited big pharma’s $250 to $300 billion in annual research spending and a $10 to $15 trillion opportunity over 20 years.
- Policy and trials: The government has put in ₹10,000 crore, but Khorakiwala warned that spending only on brick and mortar would not build the needed ecosystem. He said regulatory problems make clinical trials frustrating, despite India’s population offering the potential for faster trials, and that multinationals are more concerned about the ecosystem than price controls.
- Growth priorities: Khorakiwala said growth from chemical generics will decline amid intense competition, while India needs to move faster in biologics, where China is far ahead. Wockhardt is concentrating its biosimilar portfolio on diabetes and obesity, where it wants to build a business and dominate.
- Drug affordability: Khorakiwala said downstream markups can make a drug cost 10 times or 5 times more, which he called unacceptable, while arguing that expanding price controls could throttle competition. He suggested reviewing printed-price rules but acknowledged the issue has no simple solution.